Therefore, associations between equivalent expression of both isoforms in MEL and CON mice without mammary cancer protection and elevated PRA:PRB in MEPT mice with reduced cancer risk suggest that the combination therapy modifies the balance of the PR isoforms to a more favorable profile for diminishing mammary tumor development. Here, RB1 is linked to cancer.